The discovery of the natriuretic peptide family was a breakthrough in modern cardiovascular physiology as it provided a direct link between the heart and the kidneys in the regulation of natriuresis. Along with vasopressin and the renin-angiotensin-aldosterone system, the natriuretic peptides comprise the key peptides on which our present understanding of neuroendocrine regulation of the cardiovascular system is based. Three natriuretic peptides have been identified; the A-type, B-type and C-type natriuretic peptides. The former two, the A-and B-type natriuretic peptides, function mainly in the cardiovascular system and comprise the cardiac natriuretic peptides. Together with our increased understanding of the neurohormonal regulation of the cardiovascular system in recent years, the discovery of the natriuretic peptide family was important in the establishment of the new field of cardiovascular endocrinology.
Overview and history
thought to be a regulator of intravascular volume [4] . Further advancement was made by Currie [5] who showed The history of the research on the natriuretic peptides that the fraction showing natriuretic activity co-migrated can be traced back to 1956 when early studies using the with intestinal relaxation activity. This was an important electron microscope showed that granules similar to those finding as it allowed for fractionation and identification of in endocrine glands were found in the cells of the atria [1] .
atrial natriuretic peptide using gut smooth muscle relaxaAt the time, vasopressin and the renin-angiotensin-aldostion as an assay for activity. The further purification and terone system were known as regulators of natriuresis, but characterization of the factor by various groups throughout it was thought that there was another factor (called the the world led to the discovery of atrial natriuretic factor, 'third factor') which participates in natriuresis. It was also the first of the natriuretic factors, in 1983 and 1984 [6,7] . known from a clinical standpoint that natriuresis occurs Important in the identification of the peptide by Kangawa following supraventricular attacks which suggested that and Matsuo was the use of heat to inactivate degrading this 'third factor' was linked to the heart [2] .
enzymes which enabled them to sequence and identify an A major discovery and advancement in the identification intact peptide which had not been degraded by proteases. of atrial natriuretic peptide was made by de Bold in 1981 Subsequent studies were aimed at discovering family who showed that intravenous injection of atrial myocardial members which resulted in the isolation of two other extract causes a rapid and potent natriuretic response in factors which were named brain natriuretic peptide (BNP) rats [3] . The hypothesis for this study was based on the and C-type natriuretic peptide (CNP) [8, 9] . It is important fact that the numbers of atrial granules fluctuated with to note that these factors were known to exist as peptides intravascular volume, and thus these atrial granules were based on studies by Matsuo who showed two activities (later determined to be BNP and CNP) which co-fractionated with ANP that showed intestinal relaxation activity.
Studies also showed that although BNP was first isolated yl-terminal fragment. The carboxyl-terminal 28 amino acid from the brain, that it is predominantly expressed in the fragment is the biologically active peptide and has a ventricle. ANP and BNP were therefore renamed A-type shorter half-life than the amino-terminal fragment. Similarand B-type natriuretic peptide, respectively, to better ly, BNP is produced as a 108 amino acid precursor protein reflect their position in the family and to also lessen the which is cleaved into a biologically active 32 amino acid misleading nature of the nomenclature of BNP as a carboxyl-terminal fragment and a 76 amino acid aminocardiovascular and not a neural factor. ANP and BNP are terminal fragment. CNP produces 22 and 53 amino acid the natriuretic peptides which are expressed predominantly fragments with the former contained within the latter. The in the atria and ventricle, respectively, and are referred to 22 amino acid fragment is the mature and more active as the cardiac natriuretic peptides. CNP is differentially form, and is expressed in the nervous system and endoexpressed mainly in the nervous system and vasculature thelial cells. The common property of the natriuretic (e.g. endothelial cells, monocyte / macrophages) and is peptides is the formation of a disulfide bond which results involved mainly in neural regulation as well as vascular in a ringed-structure (Fig. 1) . The amino acids in the control although its role is still unclear.
ringed-structure are highly conserved, and this structure is necessary for binding to its receptors. In contrast, the amino acids either amino-terminal or carboxyl-terminal to 2. Biochemical structure and properties the ringed structure are quite divergent. As for the carboxyl-terminal tail, ANP and BNP have respectively five and Each natriuretic peptide is coded by a separate gene but six amino acid residues whereas CNP completely lacks this shows similar exon-intron properties suggestive of a tail. The carboxyl-terminal amino acids of BNP affect its common evolutionary ancestor. In humans, the ANP and activity and its amino acid sequence is quite diverse among BNP genes are located 8 kilobases apart on chromosome 1 species. and the CNP gene is located on chromosome 2 which is suggestive of evolutionary conservation between the cardiac natriuretic peptides ANP and BNP which is distinct 3. Receptors and mode of action from the predominantly neural peptide CNP [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . At the cDNA level, BNP shows the least similarity among
The actions of the natriuretic peptides are modulated species but is unique in that a repetitive ATTTA-motif is through their cognate receptors. Three receptors have been found in the 39-UTR. Although the precise role and cloned to date which are known as the ANP-A (a.k.a. mechanism of action of the ATTTA-motif is unknown, it NPR-A, GC-A), ANP-B (a.k.a. NPR-B, GC-B) and ANP-C is thought to regulate the half-life of mRNA and is (a.k.a NPR-C) receptors [21] [22] [23] [24] [25] [26] [27] (see Fig. 2 ). The ANP-A commonly found in genes such as the interferons and and ANP-B receptors form tetramers on the cellular lymphokines whose expression is increased in response to membrane and have intracellular kinase and guanylate physiological stimuli then are rapidly degraded after loss cyclase catalytic domains, and are thus involved in the of stimuli [20] .
cGMP-dependent signaling cascade. The ANP-C receptor The gene product (i.e. protein) is highly conserved lacks an intracellular domain. ANP and BNP both bind the among species with ANP and CNP showing greater ANP-A receptor with ANP to a higher preference than similarity across species as compared to BNP. Each BNP. A BNP selective receptor has not yet been found. natriuretic peptide gene produces a prohormone or pre-CNP shows high affinity for the ANP-B receptor. The cursor protein. ANP is synthesized as a 126 amino acid ligand-binding domains of ANP-A and ANP-B show precursor protein which is cleaved to produce a 96 amino significant homology, and ligand binding to the receptor acid amino-terminal fragment and a 28 amino acid carboxregulates activity of the intracellular catalytic domain through allosteric effects. The ANP-C receptor is thought comprise a part of the neurohormonal control network of to be involved in the clearance of the natriuretic peptides, the cardiovascular system. ANP and BNP are major but recent studies have also shown that it regulates cellular antagonizing agents of the renin-angiotensin-aldosterone functions via coupling to g-proteins as well as the adenlyl system. In heart failure, ANP reduces pulmonary artery cyclase / cAMP system [28] [29] [30] [31] [32] . The ANP-A and ANP-B wedge pressure and systemic vascular resistance (i.e. receptors differ in their expression; the ANP-A receptor is reduction of preload and after load) while increasing stroke abundant in large blood vessels in contrast to the ANP-B volume as well as a natriuretic and diuretic responses, and receptor which is predominant in the brain. Both are inhibits production of renin, aldosterone and norepinephcommonly found in the adrenal glands and kidneys. In rine. ANP contributes to vasorelaxation and natriuresis addition to clearance by the ANP-C receptor, they are also without additional activation of vasoconstricting neurocleaved by neutral endopeptidase. Neutral endopeptidase is hormones as well as sympathetic nerve control but vasodiexpressed in various tissues and recognizes all of the lation is attenuated in advanced heart failure [35, 36] . BNP natriuretic peptides although it has a greater affinity for shows similar pharmacological effects but does not reduce CNP than for ANP or BNP. ANP shows higher affinity norepinephrine levels. Atrial wall tension and increased than BNP for both the ANP-C receptor and neutral intravascular volume are hemodynamic stimuli which endopeptidase. The ANP-C receptor and neutral endoincrease the release of ANP. CNP is distinct as its secretion peptidase are thought to contribute in a combinatorial is little affected by hemodynamic stimuli. The actions of manner to the clearance of the natriuretic peptides.
CNP in the cardiovascular system are likely to have a paracrine regulatory role on vascular tonus.
Pharmacological effects 5. Animal genetic models
As hormones, the natriuretic peptides exert both peripheral as well as central (e.g. neural) effects [33, 34] .
Early studies using spontaneous hypertensive rats (SHR) ANP and BNP show common properties; CNP, however, is and stroke prone rats (SHR-SP) rats both showed increased not natriuretic and is distinct in its properties. Peripheral gene expression and secretion of ANP from the ventricles effects include (1) natriuresis, (2) vasodilation, (3) inhibisuggesting that ANP is secreted from the ventricles in tion of the renin-angiotensin and aldosterone system, and hypertensive hypertrophic hearts [37] . Studies using car-(4) anti-mitogenic effects on endothelial, smooth muscle diomyopathic hamsters have shown that ANP synthesis in and myocardial cells. Central effects include (1) thirst the ventricle is increased proportionate to the severity of (water drinking) inhibition, (2) inhibition of salt appetite, heart failure [38, 39] . These studies collectively showed in (3) antipressor effects, and (4) inhibition of the hormones animal models that ANP is released from the ventricles in ADH and ACTH. Hormones such as endothelin, vasresponse to hemodynamic stress. opressin and the catecholamines stimulate the secretion of Transgenic as well as knockout mice are now available ANP, and with the renin-angiotensin-aldosterone system for ANP and BNP. ANP as well as BNP transgenic mice showed chronic hypotension and reduced cardiac mass understanding states in which there is cardiac stress. [40] [41] [42] . ANP knockout mice showed salt-sensitive hyIschemic myocardium is also associated with elevated pertension suggestive of a role of this factor in saltcardiac natriuretic peptide levels. In acute myocardial sensitive hypertension [43] . BNP knockout mice did not infarction, BNP levels show two peaks, initially in the first show salt-sensitive hypertension but instead showed car-24 h and then again at the first week after onset. The first diac fibrosis in response to ventricular pressure overload peak is thought to correlate with impairment in cardiac which suggests BNP is a cardiovascular anti-fibrotic factor function, and the latter peak to reflect cardiac remodeling possibly involved in cardiac remodeling [44] . In contrast, [56, 57] . Importantly, the cardiac natriuretic peptides are ANP-A knockout mice showed salt-resistant hypertension the only available biochemical marker of the cardiac which suggests that the ANP-A signaling pathway can function. Biochemical diagnosis is non-invasive, fast, easy operate independently of ANP to dominate at the level of (e.g. non-technical) and cost-effective. Non-cardiologists peripheral resistance [45] .
will likely benefit most from use of this marker (e.g. hematologist using cardiac natriuretic peptide levels to diagnose the cardiac state in anthracycline cardiotoxicity 6. Clinical implications [54] ). Circulating cardiac natriuretic peptide levels used as a diagnostic marker with other screening methods such as One of the important facets of the pathophysiological chest X-ray and the electrocardiograph which are imaging profile of the natriuretic peptides is the magnitude of and electrophysiological methods, respectively, should fluctuation in circulating levels in pathogenic states. For allow for a comprehensive and improved diagnosis of the BNP, circulating levels are at times increased by up to cardiac state similar to the present combined use of 1000 times of normal levels. Hormones act by binding to biochemical, imaging and electrophysiological procedures their receptors; down-regulation of these receptors in states in the diagnosis of acute myocardial infarction [55] . of elevated hormonal levels act to negate the response of the hormonal stimuli. An important aspect of the cardiac natriuretic peptides is that infusion of ANP or BNP in 7. Conclusions patients with cardiac dysfunction induces a natriuretic response. This property of the cardiac natriuretic peptides
The natriuretic peptides since their discovery approxihas been exploited for their therapeutic effects. Recombimately 20 years ago have now been firmly established as nant ANP has been used for five years in Japan as being key factors in the regulation of intravascular volume treatment of congestive heart failure. Diuretic as well as and cardiovascular hemostasis, and have been critical in vasodilatory effects are useful in acute heart failure cases, the establishment of the new field of cardiovascular although adverse hypotensive effects are at times seen.
endocrinology [58] [59] [60] . Not only do the cardiac natriuretic Little, however, is known of the kinetics in the long term peptides play an important role in cardiovascular physibut use may be limited due to either or both receptor ology but their applied use to the diagnosis and treatment down-regulation and / or loss of effect due to decreased of cardiovascular disease is presently an important topic of intravascular volume. Lack of an oral agent is also a current research. Future studies while still necessary to limitation for long term use. BNP (e.g. Nesiritide) agents understand the complex regulation of the cardiac natas well as endopeptidase inhibitors are also presently being riuretic peptides will be important as a further step in developed.
advancing the medicine of cardiovascular endocrinology. Quantitative assessment of circulating levels of the cardiac natriuretic peptides has also been shown to be important to assess the degree of cardiac dysfunction References [38, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . Plasma ANP and BNP levels are both elevated in cardiac dysfunction in patients with heart failure.
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